For instance, the SURMOUNT-OSA (NCT05412004) study, a 52-week, phase III randomised controlled trial, is underway to explore the efficacy and safety of tirzepatide (a GLP-2 and GIP receptor agonist) in the treatment of OSA. The gene discussed is GCG; the disease is obstructive sleep apnea syndrome.